Chongqing Pharscin Pharmaceutical Co., Ltd. announced that its Ethylenediamine Diaceturate for Injection, in 0.2 gram and 0.4 gram strengths, has received a drug re-registration approval notice issued by the Chongqing Medical Products Administration. The approval number is valid until February 20, 2032, and the drug has a shelf life of 24 months. The product is indicated for the prevention and treatment of bleeding from various causes. Because it has not been produced for a long time, the company must apply to the municipal drug regulatory authority and pass on-site inspection and sampling tests before it can be marketed and sold. The company stated that this re-registration will ensure normal production and sales of the drug and will not have a significant impact on operating performance in the short term.
Chongqing Pharscin Pharmaceutical Co LtdDrug re-registration approval ensures normal production and sales, though short-term impact limited.
